-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »SEARCH RESULT
Total Matching Records found : 4195
Sugar at ration shops may dry up in 15 states next month-Indivjal Dhasmana
-The Business Standard States yet to invite tenders after partial decontrol of sugar was implemented Partial decontrol of sugar might augur well in the long run but not before giving teething troubles. Sugar supplies in ration shops of around 15 states might end from June 1, as these states have not started inviting tenders for supply, as is required under a new mechanism. Officials said only Andhra Pradesh, Kerala, Tamil Nadu, Goa, Madhya Pradesh,...
More »From Bofors to 2G, the same fate-Arun Kumar
-The Hindu The parliamentary committees on the howitzer scam and the stock market scandal protected the powerful and failed to fix accountability. The same is true in the spectrum case The current political situation brings back memories of 1989. The Prime Minister then was under a cloud in the Bofors scam. Many of his close associates like Lalit Suri and Ajitabh Bachchan were accused of wrong-doing. Today, Prime Minister Manmohan Singh and...
More »Ranbaxy case may take a toll on other Indian drug makers
-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...
More »Ranbaxy's dark chapter-Bhupesh Bhandari
-The Business Standard Why have Indian authorities woken up to the Ranbaxy case only now? The matter had been simmering for several years The Ranbaxy affair is one of the darkest chapters of India's business history. The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a penalty to settle the case. It is worse than Ramalinga...
More »
